Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 12, 2019 - Issue
Submit an article Journal homepage
235
Views
23
CrossRef citations to date
0
Altmetric
Original Research

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma

J Mark FitzGerald1 Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, BC, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8753-6056View further author information
ORCID Icon,
Eugene R Bleecker2 Divisions of Pharmacogenomics and Genetics, Genomics and Precision Medicine, University of Arizona College of Medicine, Tucson, AZ, United StatesORCID Iconhttps://orcid.org/0000-0002-4767-3494View further author information
ORCID Icon,
Arnaud Bourdin3 Department of Respiratory Diseases, Hôpital Arnaud De Villeneuve, Montpellier, FranceORCID Iconhttps://orcid.org/0000-0002-4645-5209View further author information
ORCID Icon,
William W Busse4 Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, United StatesORCID Iconhttps://orcid.org/0000-0003-2591-4696View further author information
ORCID Icon,
Gary T Ferguson5 Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, United StatesView further author information
,
Laura Brooks6 AstraZeneca, Gaithersburg, MD, United StatesView further author information
,
Peter Barker6 AstraZeneca, Gaithersburg, MD, United StatesView further author information
&
Ubaldo J Martin6 AstraZeneca, Gaithersburg, MD, United StatesORCID Iconhttps://orcid.org/0000-0002-0089-7677View further author information
ORCID Icon show all
Pages 401-413 | Published online: 09 Dec 2019

References

  • Global Asthma Network. The global asthma report. 2018 Available from: http://www.globalasthmareport.org/Global Asthma Report 2018.pdf. Accessed October 25, 2019.
  • Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.0020201324337046
  • O’Byrne PM, Pedersen S, Schatz M, et al. The poorly explored impact of uncontrolled asthma. Chest. 2013;143(2):511–523. doi:10.1378/chest.12-041223381316
  • Zhang JY, Wenzel SE. Tissue and BAL based biomarkers in asthma. Immunol Allergy Clin North Am. 2007;27(4):623–632. doi:10.1016/j.iac.2007.09.00317996580
  • Price D, Wilson AM, Chisholm A, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy. 2016;9:1–12. doi:10.2147/JAA.S9797326793004
  • Talini D, Novelli F, Bacci E, et al. Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study. BMJ Open. 2015;5(1):e005748. doi:10.1136/bmjopen-2014-005748
  • Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–1353. doi:10.1016/j.jaci.2010.04.00420513525
  • Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–29. doi:10.1016/j.rmed.2016.01.00326775606
  • Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-127609408
  • FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-827609406
  • Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa170350128530840
  • Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59. doi:10.1016/S2213-2600(18)30406-530416083
  • Wen T, Rothenberg ME. The regulatory function of eosinophils. Microbiol Spectr. 2016;4(5).
  • Ramirez GA, Yacoub MR, Ripa M, et al. Eosinophils from physiology to disease: a comprehensive review. Biomed Res Int. 2018;2018:9095275. doi:10.1155/2018/909527529619379
  • Hastie AT, Moore WC, Li H, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol. 2013;132(1):72–80. doi:10.1016/j.jaci.2013.03.04423706399
  • Fowler SJ, Tavernier G, Niven R. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. J Allergy Clin Immunol. 2015;135(3):822–824. doi:10.1016/j.jaci.2014.09.03425445828
  • Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115–120. doi:10.1136/thoraxjnl-2014-20563425422384
  • Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52(4):1800936. doi:10.1183/13993003.00936-201830139780
  • FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51–64. doi:10.1016/S2213-2600(17)30344-228919200
  • Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058–2070. doi:10.1016/j.clinthera.2016.07.01027553751
  • Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–1751. doi:10.1016/j.jaci.2018.09.03330359681

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.